Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France.
Department of Medical Oncology, Center for Medical Education and Clinical Research (CEMIC), Buenos Aires, Argentina.
Q J Nucl Med Mol Imaging. 2020 Jun;64(2):162-174. doi: 10.23736/S1824-4785.20.03250-1. Epub 2020 Feb 27.
Over the last decade, immune checkpoint inhibitors (ICI) have completely changed the treatment strategy and the prognosis of several solid cancer types. There is a lack of biomarkers to differ between responders and non-responders to these therapies. The development of biomarkers for immunotherapy has been mainly focused on tumor-related factors. The role of PD-L1 expression or tumor mutational burden (TMB) as potential predictive biomarkers for ICI efficacy is not universal and remains controversial. Moreover, leukocyte and neutrophil counts in blood samples have been used to develop clinical indicators of systemic inflammation like the neutrophil to lymphocyte ratio (NLR) and derived neutrophil to lymphocyte ratio (dNLR) based on the host immunologic status to respond against cancer cells by the immune-effectors. The Lung Immune Prognostic Index (LIPI) score have been developed as a reliable tool to assess the risk stratification of patients with cancer and to guide treatment decisions in the era of personalized cancer treatments. We review the clinical evidence supporting the use of the LIPI index as a clinically valuable biomarker for patients with NSCLC and other solid tumor types, treated with immunotherapy.
在过去的十年中，免疫检查点抑制剂 (ICI) 彻底改变了几种实体癌的治疗策略和预后。目前缺乏生物标志物来区分这些疗法的应答者和无应答者。免疫治疗生物标志物的开发主要集中在肿瘤相关因素上。PD-L1 表达或肿瘤突变负担 (TMB) 作为 ICI 疗效的潜在预测生物标志物的作用并不普遍，仍然存在争议。此外，血液样本中的白细胞和中性粒细胞计数已被用于根据宿主免疫状态开发临床炎症指标，如中性粒细胞与淋巴细胞比值 (NLR) 和衍生的中性粒细胞与淋巴细胞比值 (dNLR)，以通过免疫效应细胞对癌细胞产生反应。Lung Immune Prognostic Index（LIPI）评分已被开发为一种可靠的工具，用于评估癌症患者的风险分层，并指导个性化癌症治疗时代的治疗决策。我们回顾了支持将 LIPI 指数作为 NSCLC 和其他实体瘤类型患者接受免疫治疗的临床有价值的生物标志物的临床证据。
